Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ruxolitinib monotherapy Variant #01 | — | R 60 650 | 28d | — | — | — | — | 2 |
Pomalidomide and Prednisone Variant #02 | — | R 19 187 | 28d | — | — | — | — | — |
Lenalidomide monotherapy N/A - secondary systemic drug | — | R 6 361 | 90d | ~39.0 mo | ~113.8 mo | ~14 | ~R 89 057 PFS proxy · indirect | 10 |
Danazol monotherapy Variant #01 | — | R 1 870 | 112d | — | — | — | — | — |
Hydroxyurea monotherapy Variant #01 | — | R 278 | 28d | — | ~243.6 mo | — | — | — |
Prednisone monotherapy Variant #11 | — | R 22 | 7d | ~2.2 mo | ~14.1 mo | ~10 | ~R 215 PFS proxy · indirect | 8 |
Pomalidomide monotherapy N/A - secondary systemic drug | — | R 0 | 28d | ~2.7 mo | — | ~3 | ~R 0 PFS proxy · indirect | 1 |
Fedratinib monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
Placebo Partial | — | — | — | ~4.2 mo | ~8.0 mo | — | — | 145 |
Pacritinib monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
10 of 10 regimens shown